- ISIN
- US81642T2096
- CUSIP
- 81642T209
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 29, 2017
Highlights
- Market Cap
- $1.86B
- Enterprise Value
- $1.76B
- EPS (TTM)
- -$0.20
- EBITDA (TTM)
- -$23.82M
- Year Range
- $1.39 - $15.88
- Target Price
- $2.80
- ROA (TTM)
- -25.80%
- ROE (TTM)
- -27.42%
- Avg. Volume (1M)
- 8M
- Avg. Volume Value (1M)
- $99.94M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SLS Performance Chart
SELLAS Life Sciences Group, Inc. (SLS) is up 165.5% since the beginning of the year. At $10 per share, SLS is trading 37.0% below its 52-week high of $16. Investors who bought $1,000 worth of SLS shares 5 years ago would now be looking at an investment worth $1,169.
Loading charts...
Compare this symbol against anything
Returns By Period
SELLAS Life Sciences Group, Inc. (SLS) has returned 165.52% so far this year and 503.01% over the past 12 months.
SELLAS Life Sciences Group, Inc.
- 1D
- -2.72%
- 1M
- -33.18%
- 6M
- 165.52%
- YTD
- 165.52%
- 1Y
- 503.01%
- 3Y*
- 82.75%
- 5Y*
- 3.18%
- 10Y*
- —
- ALL TIME*
- -35.55%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
SLS Monthly Returns History
Based on dividend-adjusted daily data since Dec 29, 2017, SLS's average daily return is +0.13%, while the average monthly return is +2.29%. At this rate, an investment would double in approximately 2.6 years.
Historically, 43% of months were positive and 57% were negative. The best month was Dec 2025 with a return of +132.7%, while the worst month was Jun 2019 at -78.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, SLS closed higher 44% of trading days. The best single day was Dec 10, 2020 with a return of +176.4%, while the worst single day was Jun 14, 2019 at -57.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.00% | 30.77% | -14.20% | 17.02% | 88.08% | 58.54% | -32.18% | 165.52% | |||||
| 2025 | 55.77% | -27.16% | -8.47% | 43.52% | 10.32% | 28.07% | -27.40% | 20.75% | -16.15% | 13.04% | -10.99% | 132.72% | 262.50% |
| 2024 | -39.62% | 57.81% | 0.00% | 22.77% | 13.71% | -15.60% | -2.52% | 11.21% | -3.10% | -5.60% | -4.24% | -7.96% | -1.89% |
| 2023 | 40.68% | -49.10% | -15.38% | -1.75% | 22.06% | -8.45% | 4.46% | -10.37% | 11.56% | -40.85% | 7.21% | 1.92% | -55.08% |
| 2022 | -3.44% | 14.23% | 9.51% | -59.28% | 12.13% | -26.89% | 14.80% | 19.53% | -33.99% | 131.68% | -48.93% | -1.26% | -57.32% |
| 2021 | 4.99% | 33.28% | 5.04% | -7.73% | 51.78% | -7.19% | -22.88% | 8.53% | -1.40% | -5.13% | -22.44% | -17.95% | -4.82% |
Benchmark Metrics
SELLAS Life Sciences Group, Inc. has an annualized alpha of 23.21%, beta of 0.81, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since December 29, 2017.
- This stock participated in 198.31% of S&P 500 Index downside but only 23.14% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 23.21%
- Beta
- 0.81
- R²
- 0.01
- Upside Capture
- 23.14%
- Downside Capture
- 198.31%
Return for Risk
Risk / Return Rank
SLS ranks 98 for risk / return — above 98% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for SELLAS Life Sciences Group, Inc. (SLS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SLS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.80 | ||
| Sortino ratioReturn per unit of downside risk | +2.12 | ||
| Omega ratioGain probability vs. loss probability | 1.47 | 1.25 | +0.22 |
| Calmar ratioReturn relative to maximum drawdown | 14.74 | 2.00 | +12.74 |
| Martin ratioReturn relative to average drawdown | 31.81 | 8.49 | +23.32 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the SELLAS Life Sciences Group, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the SELLAS Life Sciences Group, Inc. was 99.89%, occurring on Jan 26, 2024. The portfolio has not yet recovered.
The current SELLAS Life Sciences Group, Inc. drawdown is 97.77%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.89%Jan 2024 | 5y 9mo | — | 8y 4moApr 2018 - now | — |
-60.34%Mar 2018 | 3mo | 5d | 3mo 5dDec 2017 - Apr 2018 | — |
Drawdown Indicators
| SLS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.89% | -56.78% | -43.11% |
Max Drawdown (1Y)Largest decline over 1 year | -36.24% | -9.10% | -27.14% |
Max Drawdown (3Y)Largest decline over 3 years | -72.20% | -18.90% | -53.30% |
Max Drawdown (5Y)Largest decline over 5 years | -95.19% | -25.43% | -69.76% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.77% | -1.58% | -96.19% |
Average DrawdownAverage peak-to-trough decline | -93.97% | -10.70% | -83.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.76% | 2.14% | +14.62% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of SELLAS Life Sciences Group, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how SELLAS Life Sciences Group, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SLS in comparison with other companies in the Biotechnology industry. Currently, SLS has a P/B value of 16.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SLS
Add SELLAS Life Sciences Group, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SLS